Network meta-analysis of 60 studies (4633 patients) in advanced BRAF-mutated colorectal cancer: first line, doublet chemotherapy plus anti-EGFR/BRAF was associated with the best overall survival, vs doublet chemotherapy plus anti-VEGF (HR 0.49, 95% CrI 0.36–0.66).
Meta-analysisn = 4,633
Qin et al. Targeted therapy in advanced BRAF-mutated colorectal cancer: systematic review and network meta-analysis